Article ; Online: Systematic Review and Meta-Analysis of Seasonal Malaria Chemoprevention.
The American journal of tropical medicine and hygiene
2023 Volume 110, Issue 1, Page(s) 20–31
Abstract: Seasonal malaria chemoprevention (SMC) for children under 5 years of age for up to four monthly cycles during malaria transmission season was recommended by the WHO in 2012 and has been implemented in 13 countries in the Sahel, reaching more than 30 ... ...
| Abstract | Seasonal malaria chemoprevention (SMC) for children under 5 years of age for up to four monthly cycles during malaria transmission season was recommended by the WHO in 2012 and has been implemented in 13 countries in the Sahel, reaching more than 30 million children annually. Malaria control programs implementing SMC have asked the WHO to consider expanding the age range or number of monthly cycles. We conducted a systematic review and meta-analysis of SMC among children up to 15 years of age and up to six monthly cycles. Twelve randomized studies were included, with outcomes stratified by age (< 5/≥ 5 years), by three or four versus five or six cycles, and by drug where possible. Drug regimens included sulfadoxine-pyrimethamine + amodiaquine, amodiaquine-artesunate, and sulfadoxine-pyrimethamine + artesunate. Included studies were all conducted in Sahelian countries in which high-grade resistance to sulfadoxine-pyrimethamine was rare and in zones with parasite prevalence ranging from 1% to 79%. Seasonal malaria chemoprevention resulted in substantial reductions in uncomplicated malaria incidence measured during that transmission season (rate ratio: 0.27, 95% CI: 0.25-0.29 among children < 5 years; rate ratio: 0.27, 95% CI: 0.25-0.30 among children ≥ 5 years) and in the prevalence of malaria parasitemia measured within 4-6 weeks from the final SMC cycle (risk ratio: 0.38, 95% CI: 0.34-0.43 among children < 5 years; risk ratio: 0.23, 95% CI: 0.11-0.48 among children ≥ 5 years). In high-transmission zones, SMC resulted in a moderately reduced risk of any anemia (risk ratio: 0.77, 95% CI: 0.72-0.83 among children < 5 years; risk ratio: 0.70, 95% CI: 0.52-0.95 among children ≥ 5 years [one study]). Children < 10 years of age had a moderate reduction in severe malaria (risk ratio: 0.53, 95% CI: 0.37-0.76) but no evidence of a mortality reduction. The evidence suggests that in areas in which sulfadoxine-pyrimethamine and amodiaquine remained efficacious, SMC effectively reduced malaria disease burden among children both < 5 and ≥ 5 years old and that the number of cycles should be commensurate with the length of the transmission season, up to six cycles. |
|---|---|
| MeSH term(s) | Child ; Child, Preschool ; Humans ; Amodiaquine/therapeutic use ; Antimalarials/therapeutic use ; Artesunate/therapeutic use ; Chemoprevention/methods ; Drug Combinations ; Malaria/epidemiology ; Malaria/prevention & control ; Malaria/drug therapy ; Pyrimethamine/therapeutic use ; Seasons ; Sulfadoxine/therapeutic use ; Adolescent |
| Chemical Substances | Amodiaquine (220236ED28) ; Antimalarials ; Artesunate (60W3249T9M) ; Drug Combinations ; Pyrimethamine (Z3614QOX8W) ; Sulfadoxine (88463U4SM5) ; sulfadoxine-pyrimethamine-artesunate |
| Language | English |
| Publishing date | 2023-12-11 |
| Publishing country | United States |
| Document type | Meta-Analysis ; Systematic Review ; Journal Article |
| ZDB-ID | 2942-7 |
| ISSN | 1476-1645 ; 0002-9637 |
| ISSN (online) | 1476-1645 |
| ISSN | 0002-9637 |
| DOI | 10.4269/ajtmh.23-0481 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ud II Zs.61: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.